News

GSK, Pfizer and CureVac

GSK to Receive $370 Million in U.S. Patent Litigation Settlement
The pharma giant will also receive a 1% royalty on future U.S. sales of influenza, Covid-19 and other related combination mRNA vaccine products made by BioNTech and Pfizer.
CureVac and GSK settle mRNA patent dispute with Pfizer and BioNTech
Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the mRNA vaccine technology that was at the forefront of the world's fight against COVID-19.
GSK, CureVac to receive $740M as COVID vaccine patent dispute with Pfizer, BioNTech settled
CureVac (NASDAQ:CVAC) announced on Friday that the company and its partner, GSK (NYSE:GSK), are set to receive $740M and other payments, as Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have agreed to resolve a patent dispute related to messenger-RNA-based COVID vaccines in the U.
GSK wins $370 million in settlement with BioNTech
UK pharma major GSK (LSE: GSK) today announced that, in connection with the mRNA patent settlement reached between CureVac (Nasdaq: CVAC) and BioNTech (Nasdaq: BNTX) on August 2025, the company will receive an upfront settlement of $370 million.
GSK wins settlement, future royalties in CureVac mRNA patent dispute
GSK said the upfront settlement amount will be recorded as other operating income in its financial results as an adjusting item in the income statement in the third quarter of 2025. The 2025 and future royalty income will be recorded in total and core results in the income statements.
Pfizer, BioNTech reach Covid jab settlement with GSK, CureVac
American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain's GSK and Germany's CureVac $740 million plus royalties to settle US legal disputes over Covid-19 vaccines, CureVac said Friday.
GSK and CureVac settle mRNA patent spat with Pfizer/BioNTech
The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation in the US – in the wake of BioNTech's recent agreement to acquire its former rival in a $1.25 billion deal.
BioNTech settles Covid-19 patent dispute with CureVac
BioNTech has agreed to pay UK drugmaker GSK royalties on its Covid-19 and influenza vaccines as part of a patent settlement with CureVac, in a deal that allows the biotech to move forward with the purchase of its German rival.
GSK to be paid up to £370 million after patent row settles in US
CureVac – a German pharmaceutical company – settled a long-running patent dispute with rival BioNTech and Pfizer in the US on Thursday.
Analytics Insight4h
FTSE 100 Live: Glencore Jumps 2.2% on Buyback News, GSK Gains on $370m Settlement
The FTSE 100 began Friday’s session on a positive note, gaining 23 points, reaching 9,124, as investors paid attention to ...
Trending tickers: Nvidia, Intel, The Trade Desk, Pinterest and GSK
James Schneider, a Goldman (GS) analyst, acknowledged that investor expectations were already “high”, but argued that Nvidia ...
GSK expects sales, profit toward top of 2025 forecasts despite tariff, pipeline pressures
GSK expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter ...
GSK Upbeat on Guidance After Specialty Medicines Boost Sales
Second-quarter sales rose to £7.99 billion from £7.88 billion in the same period the year prior.
TipRanks on MSN21h
GSK’s New Study on GSK5764227: A Potential Game-Changer in Gastrointestinal Cancer Treatment
GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...
LONDON BRIEFING: GSK wins settlement payout; FBD interim profit halves
In early corporate news, GSK wins a payout after settlement is reached in the legal action between partner CureVac and BioNTech on Thursday, while Renewables Infrastructure posts a widened interim ...
GSK Shares Drop After FDA Committee Vote Leaves Cancer-Drug Comeback in Doubt
The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work with the FDA.
Pharmaceutical Technology on MSN3d
GSK’s world-first gonorrhoea vaccine launched in England
"GSK’s world-first gonorrhoea vaccine launched in England" was originally created and published by Pharmaceutical Technology, ...